Biogen has a new rival for the BDCA2 space. AnaptysBio is picking up a distant potential challenger to the big biotech’s late-phase lupus candidate, paying Centessa Pharmaceuticals $7 million upfront for rights to a preclinical prospect that is still months away from being submitted for testing in humans..

Biogen在BDCA2空间有一个新的竞争对手。AnaptysBio正在为这家大型生物技术公司的晚期狼疮候选人寻找一个遥远的潜在挑战者，他向Centessa Pharmaceuticals支付了700万美元的预付款，以获得临床前前景的权利，该前景距离提交人体测试还有几个月的时间。。

BDCA2 is expressed exclusively on plasmacytoid dendritic cells. By binding to the antigen, antibodies can suppress the production of type I interferon and, in theory, improve outcomes in patients with diseases driven by the cytokine. Biogen reported midstage data on its drug candidate, litifilimab, in systemic lupus erythematosus last year and is running a phase 3 trial in the indication..

BDCA2仅在浆细胞样树突状细胞上表达。通过与抗原结合，抗体可以抑制I型干扰素的产生，理论上可以改善由细胞因子驱动的疾病患者的预后。Biogen去年报告了其候选药物利非单抗治疗系统性红斑狼疮的中期数据，并正在进行适应症的3期试验。。

Centessa picked up its BDCA2 program from Capella BioScience, one of the 10 biotechs it rolled up when it set up shop in 2021. Capella and Centessa have shared preclinical data on their lead BDCA2 candidate, CBS004, in systemic sclerosis, also known as scleroderma.

Centessa从Capella BioScience获得了其BDCA2项目，Capella BioScience是其2021年成立工厂时推出的10种生物技术之一。Capella和Centessa分享了他们的主要BDCA2候选人CBS004在系统性硬化症（也称为硬皮病）中的临床前数据。

Rather than take CBS004 into the clinic, Centessa, which is dissolving Capella and other U.K. businesses, has decided to offload the program to Anaptys for $7 million upfront. The fee includes a one-time cash payment of $3 million for manufactured and released GMP supply of CBS004, now renamed ANB101.

正在解散Capella和其他英国企业的Centessa没有将CBS004引入诊所，而是决定将该项目以700万美元的预付款转售给Anaptys。该费用包括一次性现金支付300万美元，用于制造和发布的CBS004 GMP供应，现更名为ANB101。

A $10 million milestone payment, in either cash or shares, is tied to the start of the first phase 3 trial..

1000万美元的里程碑付款，无论是现金还是股票，都与第一阶段3试验的开始有关。。

In a statement, Anaptys CEO Daniel Faga outlined how ANB101 fits into the biotech’s strategy, explaining that it “specifically targets plasmacytoid dendritic cells, known to be key drivers of interferon secretion and antigen presentation” and complements its “immune cell modulators to drive differentiated clinical outcomes in systemic, heterogeneous autoimmune and inflammatory diseases.”.

在一份声明中，Anaptys首席执行官丹尼尔·法加（DanielFaga）概述了ANB101如何融入生物技术的战略，解释说它“专门针对浆细胞样树突状细胞，已知它是干扰素分泌和抗原呈递的关键驱动因素”，并补充了其“免疫细胞调节剂，以驱动系统性，异质性自身免疫性和炎症性疾病的分化临床结果。”。

Anaptys is adding ANB101 to its list of candidates that are set to join its two lead programs in the clinic. The biotech plans to file to study its CD122 antagonist ANB033 in humans in the first half of next year. An IND filing for ANB101 is slated for the second half of 2024.

Anaptys正在将ANB101添加到其候选人名单中，这些候选人将加入其诊所的两个领先项目。该生物技术公司计划在明年上半年提交文件，研究其CD122拮抗剂ANB033在人体内的作用。ANB101的IND申请定于2024年下半年提交。

The candidates will sit alongside the PD-1 agonist rosnilimab and BTLA agonist ANB032 in Anaptys’ clinical-phase pipeline. Anaptys has started phase 2b trials of both candidates, in rheumatoid arthritis, ulcerative colitis and atopic dermatitis, in recent quarters, teeing up a series of data drops spanning from the end of next year through to the first half of 2026..

候选人将与PD-1激动剂rosnilimab和BTLA激动剂ANB032一起进入Anaptys的临床阶段。最近几个季度，Anaptys已开始对类风湿性关节炎、溃疡性结肠炎和特应性皮炎的两名候选人进行2b期临床试验，从明年年底到2026年上半年，出现了一系列数据下降。。

Anaptys reiterated its cash runway in the statement to disclose the licensing of ANB101. The biotech still expects its money to fund operations through the end of 2026, giving it a shot at generating clinical data that drives up its share price before needing to seek additional funding.

Anaptys在声明中重申了其现金跑道，以披露ANB101的许可证。这家生物技术公司仍然预计，到2026年底，其资金将用于运营，从而在需要寻求额外资金之前，有机会产生推动股价上涨的临床数据。